News

Vowst represents the first oral live microbiota therapeutic approved for recurrent C. difficile infections.

A study of more than 3000 Mediterranean adults is shedding light on the impact of longer midday naps on risk of metabolic syndrome, fasting glucose, and diastolic blood pressure.

In this interview, Bhutani discussed a recent peer-reviewed study which highlighted concerns over skin cancer dangers for psoriasis patients treated with methotrexate.

Data from the SURMOUNT-2 trial demonstrate use of tirzepatide 10 mg and 15 mg were associated with mean weight reductions of 13.4% and 15.7%, respectively, with more than 80% of tirzepatide users achieving a body weight reduction of 5% or greater.

The treatment is the second live microbiota therapeutic approved by the FDA, coming just a few months after the agency approved RBX2660 for recurrent C. difficile infections.

The serum glycated hemoglobin levels and the incidence of thyroid cancer in patients with type 2 diabetes in patients with type 2 diabetes were significantly higher in the observation group when compared with the control group.

Data reveal 42 SNPs associated with eosinophil counts, 18 SNPs with airway obstruction, and 21 SNPs with atopy.

An analysis of the TENAYA/LUCERNE presented at ARVO 2023 suggests faricimab more rapidly improved anatomic outcomes in patients with nAMD compared to aflibercept.

The research method, which provides better context into patient and caregiver perspective on the field, has increased nearly two-fold in prevalence since 2020.

An analysis of the phase 2/3 PHOTON trial suggested the majority of patients with DME who received aflibercept 8 mg maintained 12- or 16-week dosing intervals.

A prespecified analysis of the DELIVER trial provides insight into the effects of dapagliflozin use on total heart failure events in patients with mildly reduced or preserved ejection fraction.

New research found that certain systemic markers in psoriatic arthritis and psoriasis patients correlated with PASI scores, indicating the clinical relevance of platelets and neutrophils in inflammation.

Treatment with benzodiazepines, antipsychotics, and antidepressants was associated with an increased risk of all-cause hospitalization or mortality, while mood stabilizer treatment did not have a statistically significant association with any of the predetermined outcomes and ADHD medications were linked to a lower risk of psychiatric hospitalization.

Data from the SPRINT MIND trial suggests intensive blood pressuring-lowering was associated with slower increases in white matter lesions and improved cerebral blood flow.

Mehmi described some of the major challenges to diagnosing mucosal melanoma in patients, as well as the small amount of data around treating the rare but dangerous condition.

At week 54, there were no significant differences in patients achieving the target exposure (5 µg/mL) between those in the monotherapy cohort and those in the combination therapy cohort.

A posthoc analysis of the phase 2 CANDELA study presented at ARVO 2023 suggests aflibercept 8 mg improved visual and anatomical outcomes compared with aflibercept 2 mg in eyes with nAMD.

The majority of melatonin gummy products were inaccurately labeled, with most products exceeding the declared amount of melatonin and CBD.

At ARVO 2023, Do discusses the benefit of aflibercept 8 mg for DME in the phase 2/3 PHOTON trial, demonstrating non-inferiority in BCVA vs aflibercept 2 mg and no new safety concerns.

A retrospective analysis shows patients unresponsive to either secukinumab, ixekizumab or brodalumab may benefit from another of them.

New data from the POISE-3 trial indicates adherence to a preoperative hypotension avoidance strategy was no more effective than a hypertension-avoidance strategy for reducing risk of postoperative adverse events.

This interview featured Mehmi discussing a less well-known form of melanoma known as mucosal melanoma, a condition which he believes needs to be researched in greater depth.

In addition, 17 female patients who completed PENFS showed improvements in various symptoms, such as pain, disability, and catastrophizing, while carbohydrate degradation and LCFA synthesis pathways decreased in the post-treatment and follow-up analysis.

Presented at ARVO 2023, the nationwide data on nAMD real-world management in France suggest a discrepancy between avoiding the undertreatment of nAMD and the real-world management of the disease.

Announced on April 25, 2023, the FDA's clearance of the Omnipod GO marks the first-of-its-kind for a basal-only insulin pod and is indicated for use as an insulin delivery device for people with type 2 diabetes aged 18 or older.

An analysis of data from 3 European countries provides insight into the apparent increase in risk of atrial fibrillation associated with preterm births as well as LGA or SGA births.

Findings from a Canadian routine care study showed that brodalumab was found to be effective for those with plaque psoriasis, with future real-world setting studies needed to learn more.

Qualitative findings show children with sickle cell disease have the desire to feel normal and utilize personal strengths to manage their condition.